Welcome to our dedicated page for Amicus Therapeut SEC filings (Ticker: FOLD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Amicus Therapeutics, Inc. (NASDAQ: FOLD) SEC filings page on Stock Titan provides access to the company’s official disclosures as a rare disease biotechnology issuer. Amicus describes itself as a global, patient-dedicated biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases, including Fabry disease and late-onset Pompe disease.
Key filings for FOLD include current reports on Form 8-K that summarize material events and financial updates. For example, Amicus has filed 8-K reports to furnish press releases announcing quarterly financial results for periods ended June 30, 2025 and September 30, 2025. These filings identify the company’s common stock as listed on NASDAQ under the symbol FOLD and outline that the information provided under Item 2.02 (Results of Operations and Financial Condition) is furnished rather than filed for certain liability purposes.
Through its periodic reports and exhibits, Amicus details net product revenues for Galafold (migalastat) and Pombiliti (cipaglucosidase alfa-atga) + Opfolda (miglustat), operating expenses, non-GAAP measures and cash position. These documents also describe the company’s focus on rare disease medicines and provide context for its commercial performance and research investments.
Investors can also expect SEC filings related to significant corporate transactions. On December 19, 2025, Amicus and BioMarin Pharmaceutical Inc. announced a definitive agreement for BioMarin to acquire Amicus in an all-cash transaction, a development that would typically be reflected in transaction-related filings and proxy materials as the process advances, subject to regulatory and stockholder approvals.
On Stock Titan, Amicus filings are supplemented by AI-powered tools that help explain the content and structure of documents such as 8-Ks, quarterly reports and, when available, annual reports and proxy statements. Users can review real-time updates from EDGAR, track how Amicus reports on its rare disease portfolio and commercial performance, and examine the regulatory record that underpins analysis of FOLD as a biotechnology stock.
Amicus Therapeutics, Inc. reported an insider stock transaction by its Chief People Officer. On 12/15/2025, the officer sold 25,643 shares of common stock at $11 per share. After this sale, the officer beneficially owned 271,332 shares of Amicus Therapeutics common stock.
All of the reported transactions were carried out under a pre-established Rule 10b5-1 trading plan that the reporting person adopted on March 14, 2025, indicating the sales were made according to a predetermined schedule rather than discretionary market timing.
Amicus Therapeutics (FOLD) reported an insider transaction by its Chief People Officer. On 11/04/2025, the officer sold 25,643 shares of common stock at a $9.5098 weighted-average price (range $9.50–$9.54).
Following the sale, the officer beneficially owns 322,618 shares, held directly. The transactions were effected under a Rule 10b5-1 trading plan adopted on March 14, 2025.
Amicus Therapeutics reported stronger Q3 2025 results. Net product sales were $169.1 million, up from $141.5 million. The company posted net income of $17.3 million versus a loss a year ago. For the first nine months, sales reached $449.0 million and net loss narrowed to $28.8 million.
Galafold generated $371.5 million in year-to-date revenue, while Pombiliti + Opfolda contributed $77.5 million. Gross profit for the first nine months was $402.6 million. Operating cash flow was $16.9 million for the period. Cash, cash equivalents, and marketable securities totaled $263.8 million as of September 30, 2025.
Long-term debt carrying value was $392.0 million on a $400.0 million senior secured term loan due 2029. Inventory increased to $177.9 million to support commercial growth. The company recorded a $30 million upfront R&D expense tied to a U.S. license for Dimerix’s DMX-200. Shares outstanding were 308,533,548 as of October 24, 2025.
Amicus Therapeutics (FOLD) furnished an update on its recent performance, announcing financial results for the quarter ended September 30, 2025. The company issued a press release and will host a conference call and webcast on November 4, 2025 to discuss third‑quarter results.
The materials were provided under Item 2.02 and are furnished, not filed. Attached exhibits include the press release (Exhibit 99.1) and conference call presentation materials (Exhibit 99.2).
Amicus Therapeutics (FOLD) insider transaction: Simon N.R. Harford, identified as Chief Financial Officer and reporting person, reported a sale of 12,529 shares of Amicus common stock on 08/21/2025 at a reported price of $7.60 per share. After this transaction he is reported to beneficially own 214,898 shares. The Form 4 is signed by an attorney-in-fact on 08/25/2025.
Perceptive Advisors and related parties report a 2.4% shared ownership stake in Amicus Therapeutics (FOLD). The filing shows Perceptive Life Sciences Master Fund, Ltd. directly holds 7,412,830 shares and Perceptive Advisors LLC, as manager, and Joseph Edelman, as managing member, report shared voting and dispositive power over those shares. No sole voting or dispositive power is claimed. The ownership percentage is calculated using 308,239,374 shares outstanding. The filing states the position is not held to influence control of the company.